Michel Attal.

Its use is associated with improved myelotoxicity and increased risks of thromboembolism and second primary cancers. Together with the findings reported by McCarthy et al.,19 our data support the use of lenalidomide maintenance therapy after high-dosage chemotherapy and autologous hematopoietic stem-cell transplantation in patients with myeloma, but the impressive benefits should be weighed against the elevated risks.. Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa, M.D., Cyrille Hulin, M.D., Lofti Benboubker, M.D., Laurent Garderet, M.D., Olivier Decaux, M.D., Serge Leyvraz, M.D., Marie-Christiane Vekemans, M.D., Laurent Voillat, M.D., Mauricette Michallet, M.D., Brigitte Pegourie, M.D., Charles Dumontet, M.D., Murielle Roussel, M.D., Xavier Leleu, M.D., Claire Mathiot, M.D., Catherine Payen, M.D.D., and Jean-Luc Harousseau, M.D. Continue reading